Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Active Psoriatic Arthritis Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

Next Previous
Trial Profile

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Active Psoriatic Arthritis Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 25 Apr 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Deucravacitinib (Primary)
  • Indications Plaque psoriasis; Psoriatic arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms POETYK PsA-1
  • Sponsors Bristol-Myers Squibb

Most Recent Events

  • 06 Mar 2026 According to a Bristol-Myers Squibb media release, the U.S. Food and Drug Administration (FDA) has approved Sotyktu (deucravacitinib) for the treatment of adults with active psoriatic arthritis.
  • 27 Oct 2025 Results published in the Media Release
  • 25 Oct 2025 According to a Bristol Myers Squibb media release, result data from this study is being presented at the American College of Rheumatology (ACR) Convergence 2025 in Chicago, Illinois taking place from October 24-29, 2025..

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top